Logo image of PTHS

PELTHOS THERAPEUTICS INC (PTHS) Stock Fundamental Analysis

NYSEARCA:PTHS - US1711262048 - Common Stock

23.6505 USD
+0.66 (+2.87%)
Last: 8/29/2025, 8:04:00 PM
Fundamental Rating

0

PTHS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. PTHS has a bad profitability rating. Also its financial health evaluation is rather negative. PTHS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTHS has reported negative net income.
In the past 5 years PTHS always reported negative net income.
PTHS had a negative operating cash flow in each of the past 5 years.
PTHS Yearly Net Income VS EBIT VS OCF VS FCFPTHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

PTHS has a worse Return On Assets (-1098.30%) than 98.34% of its industry peers.
Industry RankSector Rank
ROA -1098.3%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTHS Yearly ROA, ROE, ROICPTHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTHS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTHS Yearly Profit, Operating, Gross MarginsPTHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

PTHS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, PTHS has an improved debt to assets ratio.
PTHS Yearly Shares OutstandingPTHS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PTHS Yearly Total Debt VS Total AssetsPTHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

Based on the Altman-Z score of -85.17, we must say that PTHS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PTHS (-85.17) is worse than 95.39% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.17
ROIC/WACCN/A
WACCN/A
PTHS Yearly LT Debt VS Equity VS FCFPTHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

2.3 Liquidity

A Current Ratio of 0.11 indicates that PTHS may have some problems paying its short term obligations.
PTHS has a Current ratio of 0.11. This is amonst the worse of the industry: PTHS underperforms 97.05% of its industry peers.
A Quick Ratio of 0.11 indicates that PTHS may have some problems paying its short term obligations.
The Quick ratio of PTHS (0.11) is worse than 96.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
PTHS Yearly Current Assets VS Current LiabilitesPTHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

PTHS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2876.09%.
EPS 1Y (TTM)-2876.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PTHS will show a very strong growth in Earnings Per Share. The EPS will grow by 21.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.62%
EPS Next 2Y34.04%
EPS Next 3Y24.81%
EPS Next 5Y21.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTHS Yearly Revenue VS EstimatesPTHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2026 2027 20M 40M 60M
PTHS Yearly EPS VS EstimatesPTHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PTHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTHS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTHS Price Earnings VS Forward Price EarningsPTHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTHS Per share dataPTHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as PTHS's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.04%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTHS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PELTHOS THERAPEUTICS INC

NYSEARCA:PTHS (8/29/2025, 8:04:00 PM)

23.6505

+0.66 (+2.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)N/A N/A
Inst Owners13.6%
Inst Owner ChangeN/A
Ins Owners3.83%
Ins Owner Change96.31%
Market Cap71.90M
Analysts82.86
Price Target61.2 (158.77%)
Short Float %0.71%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-900%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.08
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-2.14
TBVpS-2.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1098.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -85.17
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2876.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-3.62%
EPS Next 2Y34.04%
EPS Next 3Y24.81%
EPS Next 5Y21.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-196.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A